
Spark YG[™] 581 anti-human CD45RA

Catalog # / Size:	2120870 / 100 tests 2120865 / 25 tests
Clone:	HI100
lsotype:	Mouse IgG2b, к
Immunogen:	Human T cells from a T-ALL patient.
Reactivity:	Human, Other
Preparation:	The antibody was purified by affinity chromatography and conjugated with Spark YG™ 581 under optimal conditions.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)
Workshop Number:	IV N906
Concentration:	Lot-specific




Human peripheral blood lymphocytes were stained with anti-human CD45RO FITC and CD45RA (clone HI100) Spark YG[™] 581 (left) or only stained with anti-human CD45RO FITC (right).

Applications:

Applications:	Flow Cytomet	ry	
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. * Spark YG [™] 581 has a maximum		this s in . per be ce for Hi
	•	562 nm and a max	
Application Notes:	relevant for include: ir functions ² , staining of f	ported application mats of this hhibition of immunohistoch rozen tissue se fixed paraffin-emb sections ⁴ ,	ons (for hi clone) CD45 nemical ctions ³

immunocytochemistry^{15,16}.



Human peripheral blood lymphocytes were stained with anti-human CD4 FITC and antihuman CD25 (clone M-A251) Spark YG[™] 581 (left) or antihuman CD4 FITC only (right).

Application	 Knapp W, <i>et al.</i> 1989. Leucocyte Typing IV. Oxford University Press. New
References:	York. Yamada T, <i>et al.</i> 2002. <i>J. Biol. Chem.</i> 277:28830. (WB, Block) Weninger W, <i>et al.</i> 2003 <i>J. Immunol.</i> 170:4638. (IHC-F) Imanguli MM, <i>et al.</i> 2009. <i>Blood.</i> 113:3620 (IHC-P) Roque S, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:8028. (FC) PubMed Smeltz RB. 2007. <i>J. Immunol.</i> 178:4786. (FC) PubMed Smeltz RB. 2007. <i>J. Immunol.</i> 178:4786. (FC) PubMed Kuttruff S, <i>et al.</i> 2009. <i>Blood</i> 113:358. (FC) PubMed Kuttruff S, <i>et al.</i> 2009. <i>Blood</i> 113:358. (FC) PubMed Alanio C, <i>et al.</i> 2010. <i>Blood</i> 115:3718. (FC) PubMed Alanio C, <i>et al.</i> 2010. <i>J. Immunol.</i> 184:114. (FC) PubMed Yoshino N, <i>et al.</i> 2000. <i>Exp. Anim. (Tokyo)</i> 49:97. (FC) Guereau-de-Arellan M, <i>et al.</i> 2011. <i>Brain.</i> 134:3578. PubMed Canque B, <i>et al.</i> 2009. <i>Blood</i> 13:3620. (ICC) Imanguli MM, <i>et al.</i> 2017. Nat. Methods. 14:865. (PG) Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Description:	CD45RA is a 205-220 kD single chain type I glycoprotein. It is an exon 4 splice variant of the tyrosine phosphatase CD45. The CD45RA isoform is expressed on resting/naïve T cells, medullary thymocytes, B cells and monocytes. CD45RA enhances both T cell receptor and B cell receptor signaling. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4. CD45 has also been reported to bind galectin-1. CD45 isoform expression can change in response to cytokines.
Antigen	1. Thomas M. 1989. <i>Annu. Rev. Immunol.</i> 7:339.
References:	2. Trowbridge I, <i>et al.</i> 1994. <i>Annu. Rev. Immunol.</i> 12:85.